SOLAR-1: Alpelisib plus Fulvestrant in PIK3CA-Mutated HR-Positive, HER2-Negative Advanced Breast Cancer

Primary endpoint (PFS, PIK3CA-mutated cohort): 11.0 vs 5.7 months — HR 0.65 (95% CI 0.50–0.85; P<0.001) Key secondary (Overall survival): Not reported in this publication ORR (PIK3CA-mutated, measurable disease): 35.7% vs 16.2% Safety signal: Hyperglycemia (any grade 63.7%; grade 3: 32.7%, grade 4: 3.9%) — requires proactive monitoring and management

📱 Clinic quick reference: Mobile version — save for point-of-care use

Clinical Bottom Line

SOLAR-1 demonstrated that adding the PI3Kα-selective inhibitor alpelisib to fulvestrant nearly doubles progression-free survival in patients with PIK3CA-mutated, hormone-receptor–positive, HER2-negative advanced breast cancer who had progressed on or after aromatase inhibitor therapy. This trial established PIK3CA mutation testing as a new biomarker-driven decision point in the treatment of advanced HR-positive breast cancer and led to regulatory approval of alpelisib for this specific molecularly selected population.

The benefit was confined to patients with PIK3CA mutations — the cohort without PIK3CA-mutated cancer showed no meaningful improvement, confirming the predictive value of PIK3CA mutation status and the necessity of tumor tissue testing before initiating this therapy. In the current treatment landscape, where CDK4/6 inhibitors are first-line standard of care, alpelisib–fulvestrant occupies a role in the post–CDK4/6 inhibitor setting for patients with confirmed PIK3CA mutations, though the trial enrolled very few patients with prior CDK4/6 inhibitor exposure.

The dominant clinical concern is toxicity management. Hyperglycemia occurred in nearly two-thirds of patients receiving alpelisib, with more than a third experiencing grade 3 or higher events. Rash affected over half of patients. One in four patients discontinued alpelisib due to adverse events, and nearly two-thirds required dose reductions. These toxicities are manageable but demand proactive monitoring — particularly fasting glucose assessment, metformin prophylaxis, and dermatologic surveillance — to maintain patients on therapy long enough to realize the efficacy benefit.

Trial Overview

Study Design

• Trial name and registration: SOLAR-1, NCT02437318
• Design: Phase 3, randomized, double-blind, placebo-controlled
• Randomization: 1:1, stratified by presence or absence of lung or liver metastases and previous receipt of CDK4/6 inhibitor treatment
• Setting: HR-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer; first or second line in the advanced setting
• Enrollment period: July 26, 2015 through July 21, 2017
• Data cutoff: June 12, 2018 (PIK3CA-mutated cohort); December 23, 2016 (non-mutated cohort)

Patients were enrolled into two separate cohorts based on PIK3CA mutation status determined centrally by PCR analysis. The primary endpoint was assessed in the PIK3CA-mutated cohort only. Two interim analyses were conducted (futility at 42% of events; efficacy at 78% of events).

Mechanism of Action

Alpelisib is a selective inhibitor of the alpha isoform of phosphatidylinositol 3-kinase (PI3Kα). Gain-of-function mutations in PIK3CA, which encodes PI3Kα, are present in approximately 40% of HR-positive, HER2-negative breast cancers and lead to constitutive activation of the PI3K/AKT signaling pathway, promoting cell survival, proliferation, and resistance to endocrine therapy. By selectively targeting the mutated PI3Kα isoform, alpelisib blocks downstream signaling while sparing the other PI3K isoforms, which reduces the toxicity burden seen with pan-PI3K inhibitors [2].

Patient Population

Key eligibility: Men and postmenopausal women with locally confirmed HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously and were eligible for further endocrine therapy. Patients required adequate tumor tissue for central PIK3CA mutational analysis. ECOG performance status of 0 or 1. Measurable disease or predominantly lytic bone lesions. Patients were excluded if they had received prior chemotherapy for advanced disease, prior fulvestrant, or any PI3K/AKT/mTOR inhibitor.

Biomarker selection: PIK3CA mutation status determined centrally by PCR analysis of mutation hot spots in exons 7, 9, and 20.

Sample size flow: 1,244 screened for PIK3CA status → 1,173 with interpretable results (94.3%) → 572 randomized (341 PIK3CA-mutated: 169 alpelisib, 172 placebo; 231 non-mutated: 115 alpelisib, 116 placebo) → 571 treated (safety population: 284 alpelisib, 287 placebo).

Baseline Characteristics — PIK3CA-Mutated Cohort

Baseline characteristics were well balanced. The majority had secondary endocrine resistance. Notably, only 20 patients (5.9%) in the PIK3CA-mutated cohort had received prior CDK4/6 inhibitor therapy — a critical limitation for contemporary practice.

Treatment Protocol

Experimental Arm: Alpelisib–Fulvestrant (n=169 randomized in PIK3CA-mutated cohort; safety population n=284)

Alpelisib 300 mg per day taken orally with food (one 200-mg tablet and two 50-mg tablets), continuous daily dosing, plus fulvestrant 500 mg intramuscular injection on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles.

• Dose and schedule: Alpelisib 300 mg daily (continuous) + fulvestrant 500 mg IM per standard schedule
• Treatment duration: Until disease progression, unacceptable toxic effects, withdrawal of consent, loss to follow-up, or death
• Median treatment duration (alpelisib exposure, PIK3CA-mutated cohort): 5.5 months (IQR, 1.6 to 13.0)

• Median relative dose intensity: 82.7%

• Dose interruptions: 125 (74.0%)

• Dose reductions: 108 (63.9%)

At data cutoff, trial intervention was ongoing in 42 patients (24.9%). Progressive disease was the reason for discontinuation in 93 patients (55.0%); patient decision in 16 (9.5%).

Control Arm: Placebo–Fulvestrant (n=172 randomized in PIK3CA-mutated cohort; safety population n=287)

Matching placebo orally once daily plus fulvestrant 500 mg intramuscular injection on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles.

• Treatment duration: Until disease progression, unacceptable toxic effects, withdrawal of consent, loss to follow-up, or death
• Median treatment duration (placebo exposure, PIK3CA-mutated cohort): 4.6 months (IQR, 1.9 to 13.1)

• Median relative dose intensity: 100%

• Dose interruptions: 55 (32.2%)

• Dose reductions: 15 (8.8%)

At data cutoff, trial intervention was ongoing in 32 patients (18.6%). Progressive disease was the reason for discontinuation in 117 patients (68.0%).

Efficacy Outcomes

Primary Endpoint: Progression-Free Survival in PIK3CA-Mutated Cohort

Definition: Progression-free survival as assessed by the investigator according to RECIST v1.1

Analysis population: All randomized patients in the PIK3CA-mutated cohort (N=341; alpelisib n=169, placebo n=172)

Statistical method: Stratified log-rank test; stratified Cox regression model

Alpha allocation: 0.02 one-sided (0.0199 remaining at final analysis after 0.0001 spent at interim); Haybittle–Peto boundary for group-sequential design

Median follow-up: 20.0 months (range, 10.7 to 33.3)

Comparison: HR 0.65 (95% CI, 0.50 to 0.85; P<0.001)

The prespecified Haybittle–Peto boundary was crossed. The PFS benefit of alpelisib–fulvestrant was confirmed by a blinded independent review conducted in a random 50% subgroup: median PFS 11.1 months (95% CI, 7.3 to 16.8) versus 3.7 months (95% CI, 2.1 to 5.6); HR 0.48 (95% CI, 0.32 to 0.71).

PFS in the Cohort Without PIK3CA-Mutated Cancer

This cohort was analyzed using proof-of-concept (Bayesian) criteria with a separate, earlier data cutoff (December 23, 2016). Median follow-up was 7.4 months (range, 0.1 to 16.4).

Comparison: HR 0.85 (95% CI, 0.58 to 1.25); posterior probability of true HR <1.00: 79.4%

The proof-of-concept criteria were not met. Alpelisib did not demonstrate meaningful benefit in patients without PIK3CA-mutated cancer.

Overall Response — PIK3CA-Mutated Cohort

Overall Survival — PIK3CA-Mutated Cohort

Overall survival, the key secondary endpoint, was not reported in this publication.

Safety

Safety Population

The total safety population included 284 patients who received alpelisib–fulvestrant and 287 patients who received placebo–fulvestrant (both PIK3CA-mutated and non-mutated cohorts combined).

Safety Summary

*Dose reduction and interruption data are reported for the PIK3CA-mutated cohort only.

Grade ≥3 AE rate (combined), treatment-related AE rate, and treatment-related death rate were not reported in this publication as standard aggregate metrics.

Grade 3 and Grade 4 Adverse Events of Clinical Significance

Dashes (—) indicate grade 4 events were not reported separately for that AE in Table 3.

Adverse Events of Special Interest

⚠️ Hyperglycemia: Critical Safety Signal

• Any grade (grouped term): 65.8% (alpelisib) vs 10.5% (placebo)
• Grade ≥3 (grouped term): 38.0% (alpelisib) vs 0.7% (placebo)
• Grade 3 (single preferred term): 93 (32.7%)
• Grade 4 (single preferred term): 11 (3.9%)
• Led to discontinuation: 18 (6.3%)
• Clinical implication: Hyperglycemia is the dose-limiting toxicity of alpelisib. Fasting glucose and HbA1c should be assessed at baseline and monitored regularly (at least every 2 weeks during the first 2 months, then monthly). Patients with preexisting diabetes or prediabetes require particularly close monitoring. Metformin prophylaxis is recommended per the FDA label [2]. Dose interruption, reduction, and discontinuation algorithms are specified in the prescribing information.

⚠️ Rash: Significant Dermatologic Toxicity

• Any grade (grouped term): 53.9% (alpelisib) vs 8.4% (placebo)
• Grade ≥3 (grouped term): 20.1% (alpelisib) vs 0.3% (placebo)
• Maculopapular rash grade 3 or 4: 8.8% (alpelisib) vs 0.3% (placebo)
• Led to discontinuation: 9 (3.2%)
• Clinical implication: Rash typically occurs within the first 2 weeks and may be managed with antihistamines and topical corticosteroids. Prophylactic antihistamine use has been explored in subsequent clinical practice. Grade 3 or higher rash requires dose interruption per the prescribing information.

Gastrointestinal Toxic Effects

• Any grade (grouped term): 75.4% (alpelisib) vs 34.8% (placebo)
• Grade ≥3 (grouped term): 8.8% (alpelisib) vs 1.0% (placebo)
• Diarrhea grade 3: 19 (6.7%) vs 1 (0.3%)

Hypersensitivity

• Any grade: 16.5% (alpelisib) vs 4.2% (placebo)
• Grade ≥3: 1.8% (alpelisib) vs 0% (placebo)

Deaths

There were 19 deaths during the trial (including the 30-day postintervention safety period): 7 (2.5%) in patients receiving alpelisib–fulvestrant and 12 (4.2%) in those receiving placebo–fulvestrant. Five patients receiving alpelisib and 8 receiving placebo died from underlying breast cancer. Other deaths in the alpelisib group were due to cardiorespiratory arrest and a second primary cancer.

Treatment-related deaths as a separately reported metric were not reported in this publication.

Subgroup Analyses

Prespecified subgroup analyses of PFS in the PIK3CA-mutated cohort showed consistent benefit of alpelisib across most subgroups:

Interaction p-values were not reported in this publication.

The PFS benefit was consistent across PIK3CA mutation subtypes (E542K, E545X, H1047X), across visceral metastasis strata, and regardless of line of therapy in the advanced setting. The point estimate for the prior CDK4/6 inhibitor subgroup was favorable (HR 0.48) but the confidence interval was wide (0.17–1.36) due to the small number of patients (n=20). Notably, patients without prior chemotherapy showed an attenuated benefit (HR 0.87; 95% CI, 0.58–1.29) compared with those who had received neoadjuvant or adjuvant chemotherapy.

These subgroup analyses were prespecified and were not powered for formal statistical comparisons. Results should be interpreted as hypothesis-generating.

Key Comparator Trials

Cross-trial comparisons are limited by differences in patient populations, trial designs, and endpoints. These data are presented for context, not for direct statistical comparison.

Contextual Notes

SOLAR-1 established alpelisib as the first PIK3CA-targeted therapy to demonstrate a PFS benefit in HR-positive advanced breast cancer. However, the trial was conducted before CDK4/6 inhibitors became standard first-line therapy — only 5.9% of patients had received prior CDK4/6 inhibitors. In current practice, most patients who might receive alpelisib–fulvestrant will have progressed on CDK4/6 inhibitor–based regimens. The BYLieve trial provided supportive evidence for alpelisib efficacy in this post–CDK4/6 inhibitor population, though as a single-arm study it lacks the rigor of a randomized comparison [4].

The CAPItello-291 trial subsequently demonstrated that capivasertib (an AKT inhibitor) plus fulvestrant improved PFS in HR-positive advanced breast cancer, including in patients with PI3K/AKT/PTEN pathway alterations, many of whom had received prior CDK4/6 inhibitors [5]. This provides a partially overlapping but molecularly distinct alternative. The choice between alpelisib (PIK3CA-specific) and capivasertib (broader pathway targeting, different toxicity profile) is emerging as a key clinical decision point for molecularly characterized patients.

Grey Zones and Unanswered Questions

1. Applicability to the post–CDK4/6 inhibitor population is uncertain. Only 20 patients (5.9%) in the PIK3CA-mutated cohort had received prior CDK4/6 inhibitor therapy. While the subgroup HR (0.48) was numerically favorable, the confidence interval was extremely wide (0.17–1.36). The vast majority of patients who would receive alpelisib today have progressed on CDK4/6 inhibitor–based regimens — a population inadequately represented in SOLAR-1.

2. Overall survival data were not reported. The key secondary endpoint of OS in the PIK3CA-mutated cohort was not available at this analysis. Whether the PFS benefit translates into an OS advantage — particularly given the substantial toxicity burden — remains an open question. Subsequent analyses have provided updated OS data with mixed signals.

3. The tolerability profile may limit real-world effectiveness. The 25.0% discontinuation rate, 63.9% dose reduction rate, and 74.0% dose interruption rate raise concerns about whether the efficacy seen in the trial can be replicated in clinical practice. The median relative dose intensity of 82.7% suggests substantial dose modifications were common. Patient selection, proactive toxicity management (particularly hyperglycemia prophylaxis with metformin), and careful monitoring are essential.

4. PIK3CA mutation testing methodology may evolve. The trial used PCR-based testing of tumor tissue for specific hot-spot mutations in exons 7, 9, and 20. Whether ctDNA-based liquid biopsy testing (now FDA-approved as a companion diagnostic) identifies the same population with equal predictive value was not assessed in this primary analysis. Different testing platforms may yield discordant results in a subset of patients.

5. Comparison with capivasertib–fulvestrant has not been made directly. Clinicians now face a choice between alpelisib–fulvestrant (PIK3CA-mutated only, more hyperglycemia/rash) and capivasertib–fulvestrant (broader pathway selection, different toxicity profile) for patients with PI3K pathway-altered tumors. No head-to-head trial exists, and the optimal sequencing or selection between these agents is unknown.

Clinical Implications

Where This Fits in the Treatment Sequence

In the current (2026) treatment landscape, alpelisib–fulvestrant is positioned for patients with HR-positive, HER2-negative advanced breast cancer harboring PIK3CA mutations who have progressed on or after endocrine therapy (typically after CDK4/6 inhibitor–based first-line therapy). NCCN guidelines include alpelisib–fulvestrant as a preferred regimen option for this molecularly selected population [3].

PIK3CA mutation testing should be performed at the time of disease progression to guide treatment selection. Both tissue-based and liquid biopsy–based testing are available.

Practical Considerations

Hyperglycemia management per FDA label [2]:

• Assess fasting plasma glucose (FPG) and HbA1c before initiation
• Monitor FPG at least every 2 weeks for the first 2 months, then at least once every 4 weeks, and as clinically indicated
• Consider metformin prophylaxis or treatment for hyperglycemia
• Dose reduction levels: 300 mg → 250 mg → 200 mg → discontinue
• Hold alpelisib if FPG >250 mg/dL (repeat within 24 hours); if confirmed FPG >500 mg/dL, discontinue

Rash management:

• Monitor for rash during the first 2 weeks
• Antihistamines (prophylactic or therapeutic) and topical corticosteroids for grade 1–2
• Dose interruption for grade ≥3; systemic corticosteroids may be required

GI management:

• Nausea/diarrhea prophylaxis with antiemetics and antidiarrheals as needed
• Take alpelisib with food to improve tolerability

Post-Progression Options

Subsequent therapy rates were not reported in this publication. The non-mutated cohort analysis noted that a majority of patients went on to receive either chemotherapy or hormonal therapy plus a targeted therapy as their next treatment after progression. Post-alpelisib options in current practice include chemotherapy (capecitabine, eribulin), capivasertib–fulvestrant (if not previously used), other endocrine combinations, or clinical trials.

Regulatory and Guideline Status

Regulatory

• FDA: Alpelisib (Piqray) was approved by the FDA on May 24, 2019, in combination with fulvestrant for the treatment of postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen [2]. The therascreen PIK3CA RGQ PCR Kit (tissue) and the FoundationOne Liquid CDx (liquid biopsy) are FDA-approved companion diagnostics.
• EMA: Approved under similar indications. Regulatory status should be verified with current EMA labeling.

⚠️ Regulatory status verified as of March 2026. Confirm current approval status and labeled indications before clinical use at FDA.gov.

Guidelines

• NCCN: Alpelisib plus fulvestrant is listed as a preferred regimen option for HR-positive, HER2-negative metastatic breast cancer with PIK3CA mutation, following progression on endocrine therapy [3].

Companion Diagnostics

PIK3CA mutation testing is required before initiating alpelisib. FDA-approved companion diagnostics include the therascreen PIK3CA RGQ PCR Kit (tumor tissue) and FoundationOne Liquid CDx (ctDNA/liquid biopsy). If liquid biopsy is negative, tumor tissue testing is recommended, as liquid biopsy sensitivity may be lower in patients with low tumor burden.

About the Author

Andrew Stevenson is the founder and systems architect of kill-cancer.com, a clinical intelligence platform delivering structured, source-traced oncology trial analysis to practicing clinicians. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces directly to its source publication. Zero calculation. Zero editorializing. Zero hallucination.

Five siblings lost to cancer built the urgency. The engineering builds the trust.

📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum

Disclaimer

This article is intended for healthcare professionals only. It is not medical advice and should not be used as a substitute for professional clinical judgment. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances.

All trial data presented in this article are sourced directly from the published clinical trial report and its supplementary materials. Numbers are reproduced exactly as reported; no calculations, derivations, or estimates have been performed.

Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability.

Comparator trial data presented in Section 8 are sourced from their respective published reports and are provided for contextual purposes only. Cross-trial comparisons have inherent limitations and should not be interpreted as direct statistical comparisons.

References

1. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904
2. Piqray (alpelisib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
3. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network. Accessed March 2026.
4. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22(4):489-498.
5. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070.
6. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439.